Cantargia
CANTA | XSTO
Overview
Corporate Details
- ISIN(s):
- SE0006371126 (+3 more)
- LEI:
- 549300GKWRT7RXI4VS85
- Country:
- Sweden
- Address:
- Scheelevägen 27, 223 63 Lund
- Website:
- https://cantargia.com/en/
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
Cantargia is a Swedish biotechnology company that specializes in the development of pharmaceuticals for various types of cancer and inflammatory/autoimmune diseases. Our development programme includes the candidate drugs nadunolimab (CAN04), currently in phase IIa clinical studies, and CAN10, currently in preclinical phase, as well as our discovery project CANxx. The company is listed on OMX Stockholm’s Main List (Mid Cap). Cantargia AB was founded in 2009-2010 with the aim of refining a discovery by Professor Thoas Fioretos and Doctor Marcus Järås of Lund University. Their research showed that leukemic stem cells express a protein on their surface – IL1RAP – that is not expressed to as great a degree on normal stem cells. Further research demonstrated that this protein is also found on cancer cells from a large number of solid tumor types.
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-05-15 16:30 |
Regulatory News Service
Bulletin from the Annual General Meeting in Cantargia AB
|
English | 93.9 KB | |
| 2025-05-15 16:30 |
Regulatory News Service
Kommuniké från årsstämma i Cantargia AB
|
Swedish | 94.8 KB | |
| 2025-05-13 07:00 |
Quarterly Report
|
Swedish | 3.4 MB | |
| 2025-05-13 07:00 |
Quarterly Report
|
English | 3.4 MB | |
| 2025-03-21 10:36 |
Inside Information Statement
|
English | 9.1 KB | |
| 2025-03-12 07:00 |
Regulatory News Service
Första patienten rekryterad i Cantargias leukemistudie med nadunolimab
|
Swedish | 111.0 KB | |
| 2025-03-12 07:00 |
Regulatory News Service
First patient enrolled in Cantargia’s leukemia study with nadunolimab
|
English | 111.8 KB | |
| 2025-03-05 10:30 |
Earnings Release
Cantargia reports promising CAN10 phase 1 data from first multiple dose cohort,…
|
English | 109.7 KB | |
| 2025-03-05 10:30 |
Earnings Release
Cantargia meddelar lovande fas I-resultat från CAN10:s första grupp med multipe…
|
Swedish | 118.5 KB | |
| 2025-02-21 07:00 |
Annual Report
|
Swedish | 3.2 MB | |
| 2025-02-21 07:00 |
Annual Report
|
English | 3.2 MB | |
| 2025-02-05 20:49 |
Declaration of Voting Results & Voting Rights Announcements
|
Swedish | 8.8 KB | |
| 2025-02-05 20:05 |
Board/Management Change
Cantargia announces management changes
|
English | 105.9 KB | |
| 2025-02-05 20:05 |
Board/Management Change
Cantargia meddelar ledningsförändringar
|
Swedish | 105.0 KB | |
| 2025-01-31 13:00 |
Declaration of Voting Results & Voting Rights Announcements
Cantargia announces changes in number of shares and votes
|
English | 99.8 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-03-19 | Nedjad Losic | Other | Buy | 21,375 | 33,131.25 SEK |
| 2025-01-02 | Antonius Franciscus Berkien | Other | Other | 21,621 | 39,998.85 SEK |
| 2024-12-20 | Göran Forsberg | Other | Other | 152,206 | 281,581.10 SEK |
| 2024-12-20 | Nedjad Losic | Other | Other | 12,875 | 23,818.75 SEK |
| 2024-12-09 | Antonius Franciscus Berkien | Other | Buy | 3,741 | 6,733.80 SEK |
| 2023-01-19 | Nedjad Losic | Other | Buy | 3,918 | 29,110.74 SEK |
| 2023-01-17 | Göran Forsberg | Other | Buy | 17,000 | 140,250.00 SEK |
| 2023-01-17 | Bengt Jöndell | Other | Buy | 6,500 | 54,665.00 SEK |
| 2022-07-28 | Göran Forsberg | Other | Other | 91,765 | 344,118.75 SEK |
| 2022-07-28 | Thoas Fioretos | Other | Other | 78,400 | 294,000.00 SEK |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
ANIMALCARE GROUP PLC | United Kingdom | ANCR | |
|
Annexin Pharmaceuticals AB | Sweden | ANNX | |
|
Apontis Pharma AG | Germany | APPH | |
|
Aptahem AB | Sweden | APTA | |
|
Arctic Bioscience | Norway | ABS | |
|
ArcticZymes Technologies | Norway | AZT | |
|
argenx SE | Netherlands (Kingdom of the) | 1AE | |
|
ARIX BIOSCIENCE PLC | United Kingdom | ARIX | |
|
AroCell AB | Sweden | AROC | |
|
Arterra Bioscience | Italy | ABS |